Literature DB >> 23211287

Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.

Julian Sanz-Ortega1, Cathy Vocke, Pamela Stratton, William Marston Linehan, Maria J Merino.   

Abstract

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a hereditary cancer syndrome in which affected individuals are predisposed to the development of multiple leiomyomas of the skin and uterus and aggressive forms of kidney cancer. Affected individuals harbor a germline heterozygous loss-of-function mutation of the fumarate hydratase (FH) gene. Uterine leiomyomas are present in up to 77% of women with this syndrome. Previous studies have shown that inactivation of the FH gene is unusual for nonsyndromic leiomyomas. Therefore, it might be possible to distinguish 2 genetic groups of smooth muscle tumors: the most common group of sporadic uterine leiomyomas without FH gene inactivation and the more unusual group of HLRCC leiomyomas in patients who harbor a germline mutation of FH, although the exact prevalence of hereditary HLRCC is unknown. We reviewed the clinical, morphologic, and genotypic features of uterine leiomyomas in 19 HLRCC patients with FH germline mutations. Patients with HLRCC syndrome were younger in age compared with those with regular leiomyomata. DNA was extracted by microdissection, and analysis of loss of heterozygosity (LOH) at 1q43 was performed. Uterine leiomyomas in HLRCC have young age of onset and are multiple, with size ranging from 1 to 8 cm. Histopathologically, HLRCC leiomyomas frequently had increased cellularity, multinucleated cells, and atypia. All cases showed tumor nuclei with large orangeophilic nucleoli surrounded by a perinucleolar halo similar to the changes found in HLRCC. Occasional mitoses were found in 3 cases; however, the tumors did not fulfill the criteria for malignancy. Our study also showed that LOH at 1q43 was frequent in HLRCC leiomyomas (8/10 cases), similarly to what has been previously found in renal cell carcinomas from HLRCC patients. LOH is considered to be the second hit that inactivates the FH gene. We conclude that uterine leiomyomas associated with HLRCC syndrome have characteristic morphologic features. Both, uterine leiomyomas and renal cell carcinoma share some morphologic nuclear changes and genotypic features in HLRCC patients. The specific morphologic features of the uterine leiomyomas that we describe may help in the identification of patients who may be part of the hereditary syndrome.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23211287      PMCID: PMC3524342          DOI: 10.1097/PAS.0b013e31825ec16f

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  24 in total

1.  Inherited susceptibility to uterine leiomyomas and renal cell cancer.

Authors:  V Launonen; O Vierimaa; M Kiuru; J Isola; S Roth; E Pukkala; P Sistonen; R Herva; L A Aaltonen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

2.  Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology.

Authors:  M Kiuru; V Launonen; M Hietala; K Aittomäki; O Vierimaa; R Salovaara; J Arola; E Pukkala; P Sistonen; R Herva; L A Aaltonen
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

3.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.

Authors:  Ian P M Tomlinson; N Afrina Alam; Andrew J Rowan; Ella Barclay; Emma E M Jaeger; David Kelsell; Irene Leigh; Patricia Gorman; Hanan Lamlum; Shamima Rahman; Rebecca R Roylance; Simon Olpin; Stephen Bevan; Karen Barker; Nicholas Hearle; Richard S Houlston; Maija Kiuru; Rainer Lehtonen; Auli Karhu; Susa Vilkki; Päivi Laiho; Carita Eklund; Outi Vierimaa; Kristiina Aittomäki; Marja Hietala; Pertti Sistonen; Anders Paetau; Reijo Salovaara; Riitta Herva; Virpi Launonen; Lauri A Aaltonen
Journal:  Nat Genet       Date:  2002-02-25       Impact factor: 38.330

4.  Involvement of fumarate hydratase in nonsyndromic uterine leiomyomas: genetic linkage analysis and FISH studies.

Authors:  Karen L Gross; Carolien I M Panhuysen; Michael S Kleinman; Hilary Goldhammer; Emlyn S Jones; Najlla Nassery; Elizabeth A Stewart; Cynthia C Morton
Journal:  Genes Chromosomes Cancer       Date:  2004-11       Impact factor: 5.006

Review 5.  Genetic basis of cancer of the kidney: disease-specific approaches to therapy.

Authors:  W Marston Linehan; James Vasselli; Ramaprasad Srinivasan; McClellan M Walther; Maria Merino; Peter Choyke; Cathy Vocke; Laura Schmidt; Jennifer S Isaacs; Gladys Glenn; Jorge Toro; Berton Zbar; Donald Bottaro; Len Neckers
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

6.  Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America.

Authors:  Jorge R Toro; Michael L Nickerson; Ming-Hui Wei; Michelle B Warren; Gladys M Glenn; Maria L Turner; Laveta Stewart; Paul Duray; Ousman Tourre; Nirmala Sharma; Peter Choyke; Pamela Stratton; Maria Merino; McClellan M Walther; W Marston Linehan; Laura S Schmidt; Berton Zbar
Journal:  Am J Hum Genet       Date:  2003-05-22       Impact factor: 11.025

7.  Germline fumarate hydratase mutations in families with multiple cutaneous and uterine leiomyomata.

Authors:  Amalia Martinez-Mir; Benjamin Glaser; Gary S Chuang; Liran Horev; Arie Waldman; Danielle E Engler; Derek Gordon; Lynda J Spelman; Ioannis Hatzibougias; Jack Green; Angela M Christiano; Abraham Zlotogorski
Journal:  J Invest Dermatol       Date:  2003-10       Impact factor: 8.551

8.  Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families.

Authors:  Maija Kiuru; Rainer Lehtonen; Johanna Arola; Reijo Salovaara; Heikki Järvinen; Kristiina Aittomäki; Jari Sjöberg; Tapio Visakorpi; Sakari Knuutila; Jorma Isola; Brett Delahunt; Riitta Herva; Virpi Launonen; Auli Karhu; Lauri A Aaltonen
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

9.  Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors.

Authors:  Rainer Lehtonen; Maija Kiuru; Sakari Vanharanta; Jari Sjöberg; Leena-Maija Aaltonen; Kristiina Aittomäki; Johanna Arola; Ralf Butzow; Charis Eng; Kirsti Husgafvel-Pursiainen; Jorma Isola; Heikki Järvinen; Pasi Koivisto; Jukka-Pekka Mecklin; Päivi Peltomäki; Reijo Salovaara; Veli-Matti Wasenius; Auli Karhu; Virpi Launonen; Nina N Nupponen; Lauri A Aaltonen
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

10.  Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomas.

Authors:  K T Barker; S Bevan; R Wang; Y-J Lu; A M Flanagan; J A Bridge; C Fisher; C J Finlayson; J Shipley; R S Houlston
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640

View more
  30 in total

Review 1.  [New features in the 2014 WHO classification of uterine neoplasms].

Authors:  S F Lax
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

Review 2.  Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia.

Authors:  Esther Oliva
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

Review 3.  The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy.

Authors:  Reshef Tal; James H Segars
Journal:  Hum Reprod Update       Date:  2013-09-29       Impact factor: 15.610

4.  Expanding morphological and clinical aspects of hereditary leiomyomatosis and renal cell carcinoma (HLRCC): a case report in a patient with unusual morphology and clinical presentation.

Authors:  Isabela Werneck da Cunha; Walter Henriques da Costa; Mariana A Morini; Stephania Martins Bezerra; Dirce Maria Carraro; Giovana Tardin Torrezan; Maria Nirvana Cruz Formiga; Gustavo Cardoso Guimaraes; Stenio Cassio Zequi; Fernando Augusto Soares
Journal:  Virchows Arch       Date:  2018-08-31       Impact factor: 4.064

5.  Genetic testing of leiomyoma tissue in women younger than 30 years old might provide an effective screening approach for the hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC).

Authors:  Petr Martínek; Petr Grossmann; Ondřej Hes; Jiří Bouda; Viktor Eret; Norma Frizzell; Anthony J Gill; Ondrej Ondič
Journal:  Virchows Arch       Date:  2015-05-19       Impact factor: 4.064

6.  MED12 exon 2 mutations in histopathological uterine leiomyoma variants.

Authors:  Netta Mäkinen; Pia Vahteristo; Kati Kämpjärvi; Johanna Arola; Ralf Bützow; Lauri A Aaltonen
Journal:  Eur J Hum Genet       Date:  2013-02-27       Impact factor: 4.246

7.  Fumarase-deficient Uterine Leiomyomas: An Immunohistochemical, Molecular Genetic, and Clinicopathologic Study of 86 Cases.

Authors:  Markku Miettinen; Anna Felisiak-Golabek; Bartosz Wasag; Magdalena Chmara; Zengfeng Wang; Ralf Butzow; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2016-12       Impact factor: 6.394

Review 8.  Renal cell carcinoma: Evolving and emerging subtypes.

Authors:  Suzanne M Crumley; Mukul Divatia; Luan Truong; Steven Shen; Alberto G Ayala; Jae Y Ro
Journal:  World J Clin Cases       Date:  2013-12-16       Impact factor: 1.337

9.  Fumarate hydratase (FH) deficiency in uterine leiomyomas: recognition by histological features versus blind immunoscreening.

Authors:  Lisa Siegler; Ramona Erber; Stefanie Burghaus; Tobias Brodkorb; David Wachter; Nafisa Wilkinson; James Bolton; Helen Stringfellow; Florian Haller; Matthias W Beckmann; Arndt Hartmann; Abbas Agaimy
Journal:  Virchows Arch       Date:  2018-01-13       Impact factor: 4.064

Review 10.  Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer.

Authors:  W Marston Linehan; Tracey A Rouault
Journal:  Clin Cancer Res       Date:  2013-04-30       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.